Multistate Avandia Settlement (November 2012)
GlaxoSmithKline agreed to pay $90 million to settle claims by 37 states and the District of Columbia that the company illegally promoted its Avandia diabetes drug. The settlement resolved claims that GSK misled consumers about Avandia’s cardiovascular risks. The company did not admit to any wrongdoing or liability under the settlement. See related GlaxoSmithKline instance, “Multistate Avandia Settlement (July 2013)”.
- Misconduct Type
- Enforcement Agency
- Contracting Party
- Court Type
- Date of Settlement Announcement